Lineage Foundation for Good Celebrates One-Year Anniversary, Announces “Holidays for Good” Campaign
16.11.2022 16:00:00 EET | Business Wire | Press release
Lineage Foundation for Good (the “Foundation”), the independent philanthropic arm of Lineage Logistics, LLC (“Lineage”), recently celebrated its one-year anniversary. The nonprofit, which aims to redirect food that would otherwise go to waste and address hunger to support the social and economic mobility of our communities, has successfully donated the equivalent of 239 million meals over the past two years.
“Given recent events, global hunger and food insecurity is rising, affecting more than 800 million people,” said Christine Rees-Zecha, Board President of the Lineage Foundation for Good. “Through the Lineage Foundation for Good, we aim to leverage our network, expertise, and partnerships to prevent waste and redirect food into the communities that need it most. While there is still more work to do, I am proud of the accomplishments we achieved in the first year, including delivering more than 200 million meals to those in need, made possible by our dedicated team members.”
Last October, Lineage launched the Lineage Foundation for Good following the Company’s successful inaugural campaign, which provided 100 million meals to people in need during the height of the pandemic. In addition to supporting Lineage’s philanthropic efforts, the Foundation has sought to strengthen initiatives and organizations that align with the Company’s mission to create innovative and sustainable solutions to help reduce food waste and fight food insecurity.
At its inception, the Foundation set a goal to donate the equivalent of 500 million meals to people in need by 2025. To date, it is on track to significantly exceed this goal. As the Foundation continues to make progress on this commitment, it has also achieved notable progress in the following areas:
- Raised over $234,000 to support the Global FoodBanking Network and the Polish Humanitarian Action Organization’s efforts in response to the ongoing conflict in Ukraine.
- Supported Lineage team members and their families impacted by the conflict who returned to Ukraine to assist by continuing to pay their wages, as well as providing stipends to team members who are housing refugees and covered the relocation costs of five families.
- Contributed over 1,000 volunteer hours in communities worldwide, such as volunteering at food banks and distributing meals at community-based kitchens.
- Issued more than $1.6 million in community-based grants to local food banks, schools and other community-based organizations to help with operational costs.
- Donated over $600,000 to the Team Member Hardship Grant program, an initiative dedicated to financially supporting Lineage team members through times of hardship.
- In partnership with Penske, Darden Foundation, supported the donation of 10 refrigerated trucks to Feeding America® member food banks.
- Received a historic one-million-pound donation that will benefit six food banks within the Feeding America network.
- Grew its global network of partnerships to 50 strategic partners, which includes the Global FoodBanking Network, Feeding America, Empowerment Plan, Move for Hunger and the Darden Foundation. Through these partnerships, the Foundation has coordinated volunteer events and made charitable donations to partners.
“Over the past year, we’ve partnered with the Lineage Foundation for Good on their mission to reduce food waste and address food insecurity,” said Diane Letson, vice president of food industry partnerships at Feeding America. “With nearly 34 million people facing hunger in America, and amid the challenging inflationary environment many are experiencing, we are grateful for the recent work that Lineage and its partners accomplished in diverting one million pounds of food from going to waste and ensuring that it reached our neighbors in need.”
Building on the momentum of a successful first year, the Foundation is also launching the “Holidays for Good” Campaign to donate food to local communities during the holiday season. Beginning in November and running through the holiday season, “Holidays for Good” will contribute the equivalent of one million meals through customer product donations, food drives and volunteer events that benefit local community food banks.
For more information on the Lineage Foundation for Good, visit the Foundation page here. You can also reach out to foundation@lineagelogistics.com for information on partnership opportunities, volunteer events, and other ways to support.
About Lineage Foundation for Good
The Lineage Foundation for Good (the “Foundation”) is the independent philanthropic arm of Lineage Logistics, LLC (“Lineage”). The Foundation leverages the unique access, influence, experience, and expertise of Lineage, one of the world’s largest temperature-controlled logistics solutions providers, and its customers and partners to reduce food waste and fight food insecurity – a need that was accelerated by the practical challenges of getting quality food to those in need during the COVID-19 pandemic. Central to the Foundation’s mission is to develop a dynamic, real-time, and global link between those who commercially produce our food and the individuals, families, and communities who need it most. The Foundation creates a system in which food products, including those that might have otherwise gone to waste, can be quickly and easily steered to food pantries and other non-profits combatting food insecurity around the world. The Foundation supports various philanthropic initiatives that have an impact in the communities in which we live and work, and is proud to partner with Feeding America, the Global FoodBanking Network, and other organizations to expand its reach, maximize its impact, and help feed the world.
About Lineage Logistics
Lineage Logistics is the world’s largest temperature-controlled industrial REIT and logistics solutions provider. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity, which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network and the development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was a 2022 U.S. Best Managed Company, No. 3 in the 2022 CNBC Disruptor 50 list, No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005327/en/
Contact information
Lineage Logistics
Christina Wiese
734-608-1855
cwiese@lineagelogistics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
